Last reviewed · How we verify
MMH-MAP
MMH-MAP is a monoclonal antibody targeting the PD-1 receptor.
MMH-MAP is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | MMH-MAP |
|---|---|
| Also known as | Prospekta |
| Sponsor | Materia Medica Holding |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, MMH-MAP prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the inhibition on T cells and enhancing the immune response against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
Key clinical trials
- Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders (PHASE3)
- Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia. (PHASE3)
- Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children (PHASE3)
- Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMH-MAP CI brief — competitive landscape report
- MMH-MAP updates RSS · CI watch RSS
- Materia Medica Holding portfolio CI